advanced search

EXPERT VIEW

A POSITIVE SPIN ON DPI FORMULATION
EXPERT VIEW
Bert Dekens
A POSITIVE SPIN ON DPI FORMULATION
Bert Dekens outlines some of the considerations that go into developing and processing dry powder inhaler formulations, and discusses the merits of conical high-shear mixers.
POWDER MICRODOSING WITH 100% IN-LINE FILL WEIGHT CONTROL BY X-RAY
EXPERT VIEW
Dr Karlheinz Seyfang
POWDER MICRODOSING WITH 100% IN-LINE FILL WEIGHT CONTROL BY X-RAY
Karlheinz Seyfang discusses the need for filling verification in pre-metered DPI blister filling lines, going on to detail the role X-ray analysis could play in an automated verification process.
THE NEW EU MEDICAL DEVICE REGULATIONS – IMPLICATIONS FOR INHALATION DEVICES
EXPERT VIEW
Mary Hutchens
THE NEW EU MEDICAL DEVICE REGULATIONS – IMPLICATIONS FOR INHALATION DEVICES
Mary Hutchens gives an overview of some of the changes wrought by last year’s introduction of the new EU Medical Device Regulation, with a specific view to its effect on inhalation devices and inhaled medical products.
CHOOSING THE RIGHT DOSATOR FOR DPI DOSING
EXPERT VIEW
Jamie Clayton
CHOOSING THE RIGHT DOSATOR FOR DPI DOSING
Jamie Clayton, Rajeev Dattani and Dave Seaward discuss the operation of dosators for reliable and accurate filling of DPI capsules and blisters.
MEETING FUTURE NEEDS FOR RESPIRATORY DRUG DELIVERY DEVELOPMENT
EXPERT VIEW
Mark Knowles
MEETING FUTURE NEEDS FOR RESPIRATORY DRUG DELIVERY DEVELOPMENT
Mark Knowles and Collette Johnson explore the different elements that need to be considered when developing a smart inhalation drug delivery device to ensure that maximum benefit is obtained.
QUALITY BY DESIGN IN TDS DEVELOPMENT: BENEFIT OR BUREAUCRATIC BURDEN?
EXPERT VIEW
Petra Botzem
QUALITY BY DESIGN IN TDS DEVELOPMENT: BENEFIT OR BUREAUCRATIC BURDEN?
Petra Botzem and Thomas Hille discuss the Quality-by-Design approach to the development of transdermal drug delivery systems as laid out in ICH guideline Q8.
FROM PREFILLED SYRINGES TO COMBI-FILLING
EXPERT VIEW
Klaus Ullher
FROM PREFILLED SYRINGES TO COMBI-FILLING
Klaus Ullherr summarises the state of modern packaging technology in the pharmaceutical industry in the light of the biotech boom, ready-to-fill and pre-sterilised containers and the trend towards individualised healthcare.
RECONSTITUTION DEVICES: MIXING, POWER, PACKAGING & REGULATION
EXPERT VIEW
Charlotte Harvey
RECONSTITUTION DEVICES: MIXING, POWER, PACKAGING & REGULATION
Charlotte Harvey discusses the challenge of reconstituting lyophilised drugs, both from the perspective of the drug itself and the delivery device associated with it.
A PATIENT-CENTRIC APPROACH TO THERAPY MANAGEMENT
EXPERT VIEW
Karl Hewson
A PATIENT-CENTRIC APPROACH TO THERAPY MANAGEMENT
Karl Hewson and Uri Baruch discuss the challenges presented by chronic illness, and look ahead to a better future of patient-centric treatment, personalised to each individual’s needs.
PHYSICOCHEMICAL BIOEQUIVALENCE IN OPHTHALMIC MICROEMULSIONS
EXPERT VIEW
Dr Paul Kippax
PHYSICOCHEMICAL BIOEQUIVALENCE IN OPHTHALMIC MICROEMULSIONS
Here, Paul Kippax describes the methods by which bioequivalence can be established for ophthalmic microemulsions by in vitro testing, saving the need for costly clinical trials.
USING PHYSICAL FORCES TO ENHANCE OCULAR DRUG DELIVERY
EXPERT VIEW
Di Huang
USING PHYSICAL FORCES TO ENHANCE OCULAR DRUG DELIVERY
Di Huang, Erica Chen and Ilva Rupenthal discuss the possibilities offered by physical force-based methods of enhancing the efficacy of ophthalmic drug delivery by providing a way past the eye’s natural barriers.
SUSTAINED RELEASE OCULAR THERAPEUTICS
EXPERT VIEW
Michael O'Rourke
SUSTAINED RELEASE OCULAR THERAPEUTICS
Michael O’Rourke gives an overview of the current state of the ophthalmics market, going into greater detail on the opportunities offered in the area of sustained-release technologies and therapies.
HOW CONNECTIVITY WILL REMODEL HEALTHCARE
EXPERT VIEW
Dr Marjorie Villien
HOW CONNECTIVITY WILL REMODEL HEALTHCARE
Marjorie Villien and Jerôme Mouly provide a forecast of the place of connectivity in the healthcare market and the significant changes it is likely to bring to both devices and the market itself.
THE PROMISE OF VOICE: CONNECTING DRUG DELIVERY THROUGH VOICE-ACTIVATED TECHNOLOGY
EXPERT VIEW
Chris Franzese
THE PROMISE OF VOICE: CONNECTING DRUG DELIVERY THROUGH VOICE-ACTIVATED TECHNOLOGY
Chris Franzese and Marty Coyne discuss the vast potential that voice-activated technologies, such as Amazon’s Alexa, have in the healthcare market. Running through the challenges posed by data security and human factors, they go on to explain how the rewards voice-activation offers are well worth the effort, spanning the drug delivery experience.
ENERGY HARVESTING: POWERING CONNECTED DRUG DELIVERY DEVICES
EXPERT VIEW
Charlotte Harvey
ENERGY HARVESTING: POWERING CONNECTED DRUG DELIVERY DEVICES
Charlotte Harvey examines the opportunities and practicalities of using energy harvesting technologies in drug delivery devices. With a specific focus on enabling connectivity functionality, Ms Harvey runs through the various aspects of energy harvesting and offers insight on whether it is the right choice for a new device development.
THE LATEST DIGITAL TOOLS REVEAL ACTUAL PATIENT BEHAVIOUR
EXPERT VIEW
Ryan Noble
THE LATEST DIGITAL TOOLS REVEAL ACTUAL PATIENT BEHAVIOUR
Ryan Noble and Tom Lawrie-Fussey discuss the potential of digital innovations to improve understanding of real patient behaviour and consequently increase adherence.
KEY CONSIDERATIONS FOR NON-CLINICAL SAFETY ASSESSMENT OF INHALED BIOPHARMACEUTICALS
EXPERT VIEW
Dr Simon Moore
KEY CONSIDERATIONS FOR NON-CLINICAL SAFETY ASSESSMENT OF INHALED BIOPHARMACEUTICALS
Simon Moore, Kirsty Haprer and Sylwia Marshall highlight some of the key considerations for the development of inhaled biopharmaceuticals, including non-clinical safety assessment.
DOES THE NEW EU MDR SPELL THE END OF GRANDFATHERING?
EXPERT VIEW
Helen Simmons
DOES THE NEW EU MDR SPELL THE END OF GRANDFATHERING?
Helen Simons and Stephanie Ward describe how the new EU Medical Devices Regulation will impact on “grandfathered” devices that were approved under old regulation and are currently on the market, but do not necessarily comply with current/updated regulatory standards, and explain the potential implications for device manufacturers.
DESIGN VALIDATION TESTING – DRUG DELIVERY DEVICES
EXPERT VIEW
Mark Turner
DESIGN VALIDATION TESTING – DRUG DELIVERY DEVICES
From a regulatory perspective, Mark Turner provides a summary of the current requirements of parenteral device manufacturers in the area of design validation testing.
EVALUATING A NEW MICROSPHERE BASED CONTROLLED-RELEASE DELIVERY SYSTEM
EXPERT VIEW
Dr S Mohan Mohanraj
EVALUATING A NEW MICROSPHERE BASED CONTROLLED-RELEASE DELIVERY SYSTEM
S Mohan Mohanraj and Meir Kende discuss the development of a microsphere based delivery system for an orally administered anthrax vaccine.
TECHNOLOGIES & CLINICAL STUDIES FOR THE ORAL DELIVERY OF CALCITONIN
EXPERT VIEW
Dr Nozer Mehta
TECHNOLOGIES & CLINICAL STUDIES FOR THE ORAL DELIVERY OF CALCITONIN
Nozer Mehta, James P Gilligan and William Stern summarise the different technologies that have been in development for oral delivery of peptides through the gastro-intestinal mucosal surfaces via the transcellular or the paracellular pathways and describe the results of several long-term clinical studies on the oral delivery of salmon calcitonin.
CONNECTED COMBINATION PRODUCTS: US ANALYSIS WITH POTENTIAL IMPLICATIONS WORLDWIDE
EXPERT VIEW
Napoleon Monroe
CONNECTED COMBINATION PRODUCTS: US ANALYSIS WITH POTENTIAL IMPLICATIONS WORLDWIDE
Napoleon Monroe provides an overview of the current status of connected combination products from the US perspective, with an emphasis on human factors, automated identity and regulation.
IMPLANTS CONNECT PATIENTS FOR BETTER, FASTER, MORE PERSONALISED CARE
EXPERT VIEW
Will Rosellini
IMPLANTS CONNECT PATIENTS FOR BETTER, FASTER, MORE PERSONALISED CARE
Will Rosellini and Beth Rosellini describe the rapidly advancing area of local field potential recording of nervous system activity which has the ability to record patient data directly and has the potential to form highly advanced connected and closed-loop systems.
THE POTENTIAL OF CONNECTED DEVICES FOR TACKLING ASTHMA
EXPERT VIEW
Garth Sutherland
THE POTENTIAL OF CONNECTED DEVICES FOR TACKLING ASTHMA
Garth Sutherland and Jon-Paul Sherlock explain how a strategic partnership between pharmaceutical companies and digital health companies can achieve improved outcomes through joint initiatives.
Top